三阴性乳腺癌最新治疗及研究进展-外科学(乳腺、甲状腺、胰腺)专业论文.docxVIP

重庆 重庆医科大学硕士研究生学位论文 万方数据 万方数据 英汉缩略语名词对照 TNBC triple negative breast cancer 三阴性乳腺癌 IHC immunohistochemical 免疫组织化学 ER estrogen receptor 雌激素受体 PR progesterone receptor 孕激素受体 Her-2 human epidermal growth factor receptor-2 人表皮生长因子受体 2 ADM adriamycin 阿霉素 TPFS time to progress free survival, 无疾病进展时间 OS over survival 总生存时间 pCR pathology complete response 病理完全缓解 GHRH growth hormone releasing hormone 生长激素释放激素 HAR hematologic adverse reaction 血液学不良反应 PARPs poly-APDribose polymerase 聚-ADP 核糖聚合酶 EGFR epidermal growth factor receptor 表皮生长因子受体 VEGF vascular endothelial growth factor 血管内皮生长因子 CSCs cancer stem cells 肿瘤干细胞 TAX Docetaxel 多西他赛 UTI Ulinastatin 乌司他丁 1 三阴性乳腺癌最新治疗及研究进展 摘要 三阴性乳腺癌（triple negative breast cancer，TNBC）是乳腺 癌中的一个亚型，在免疫组织化学（immunohistochemical, IHC）上缺 乏雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）和人类表皮生长因子受体-2（human epidermal growth factor receptor-2，Her-2）表达，呈现恶性程度高、侵袭性强、复 发率高、易远处转移、易局部复发及预后差等显著特征。ER、PR 和 Her-2 的表达缺失，TNBC 的内分泌治疗和抗 Her-2 的靶向治疗效果差，治疗 手段相对于其他乳腺癌亦受到限制。目前已引起国内外学者的广泛关 注。本文就 TNBC 的临床治疗和研究新进展做一综述。 关键词：三阴性乳腺癌，病理组织学特征，治疗，生物靶向治疗 2 THE LATEST TREATMENT AND RESEARCH PROGRESS OF TRIPLE NEGATIVE BREAST CANCER ABSTRACT Triple negative breast cancer(TNBC) is a subtype of breast cancer, defined by the lack of immunohistochemical expression of the estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor-2 (HER-2),and characterized by highly aggressive, high malignant degree, high recurrence rate, distant metastasis and local recurrence and poor prognosis. Due to the lack of expression of ER, PR and HER-2, so its endocrine therapy and HER-2 targeted therapy effect is poor, its treatments relative to other breast cancer also corresponding is restricted. TNBC has aroused wide attention of scholars both at home and abroad at present. In this review, we discuss the new progress of the clinical treatment and research of TNBC. Key Words: triple negative Breast cancer ， histologic features ， treatment，Biological target therap